Bluebird bio, Inc., a renowned biotechnology company, has been actively engaged in researching, developing, and commercializing gene therapies meant for severe genetic diseases. Its diverse range of product candidates includes ZYNTEGLO (betibeglogene autotemcel) to aid in treating transfusion-dependent ß-thalassemia, lovotibeglogene autotemcel for sickle cell disease (SCD) treatment, and SKYSONA (elivaldogene autotemcel) to assist patients suffering from cerebral adrenoleukodystrophy. The company's clinical development programs incorporate HGB-205, HGB-206, and HGB-210, which are meant to assess the viability and safety of lovo-cel in treating patients with SCD, and HGB-204, HGB-205, HGB-207, and HGB-212, which are for evaluating the safety and efficacy of beti-cel in treating patients with ß-thalassemia. As a testament to its success and growth, the company has entered into a licensing agreement with Orchard Therapeutics Limited. With its headquarters located in Somerville, Massachusetts, bluebird bio, Inc. was initially known as Genetix Pharmaceuticals, Inc. before changing its name in September 2010. Founded in 1992, the company has since then revolutionized the field of biotechnology, catering to patients suffering from severe genetic diseases.